Esomeprazole in acute and maintenance treatment of reflux oesophagitis: a multicentre prospective study.

abstract：INTRODUCTION:Prostate cancer (PC) is the second leading cause of cancer death among US men and accounts for considerable healthcare expenditures. We evaluated economic outcomes in men with chemotherapy-naïve metastatic castration-resistant PC (mCRPC) treated with enzalutamide or abiraterone acetate plus prednisone (abi...

journal_title：Advances in therapy

authors： Ramaswamy K,Lechpammer S,Mardekian J,Huang A,Schultz NM,Sandin R,Wang L,Baser O,George DJ

更新日期：2020-05-01 00:00:00

abstract：INTRODUCTION:Intanza® 9 μg (Sanofi Pasteur SA, Lyon, France), a split virion trivalent influenza vaccine delivered by intradermal injection with a microinjection system, became available as a vaccination for adults aged 18 to 59 years old, as of the 2010 southern hemisphere influenza season. METHODS:This study was des...

journal_title：Advances in therapy

authors： Eizenberg P,Booy R,Naser N,Mason G,Stamboulian D,Weber F

更新日期：2011-08-01 00:00:00

abstract：:Nonketotic hyperosmolar coma (NHC) is characterized by severe hyperglycemia; absence of, or only slight ketosis; nonketotic acidosis; severe dehydration; depressed sensorium or frank coma; and various neurologic signs. This condition is uncommon in type 1 diabetes. Because of little or no osmotic diuresis in patients ...

journal_title：Advances in therapy

authors： Dogan E,Erkoc R,Sayarlioglu H,Buyukbese A

更新日期：2005-09-01 00:00:00

abstract：:Tumor necrosis factor (TNF) inhibitors are widely used biologics for the treatment of several chronic inflammatory diseases. The launch of anti-TNF biosimilars has introduced the possibility of non-medical switching between originator biologics and their biosimilars. However, the potential clinical and patient-reporte...

journal_title：Advances in therapy

authors： Numan S,Faccin F

更新日期：2018-09-01 00:00:00

abstract：INTRODUCTION:Secukinumab, a fully human monoclonal antibody that directly inhibits interleukin-17A, has demonstrated robust efficacy in the treatment of moderate to severe psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis (AS), with a rapid onset of action, sustained long-term clinical responses and...

journal_title：Advances in therapy

authors： Kiltz U,Sfikakis PP,Gaffney K,Sator PG,von Kiedrowski R,Bounas A,Gullick N,Conrad C,Rigopoulos D,Lespessailles E,Romanelli M,Ghislain PD,Brandt-Jürgens J,Rashkov R,Aassi M,Orsenigo R,Perella C,Pournara E,Gathmann S,

更新日期：2020-06-01 00:00:00

abstract：INTRODUCTION:Partial nephrectomy (PN) has evolved into the surgical standard of care for localized renal lesions. Hemostatic agents (HA) support the surgeon in achieving local hemostasis during PN. We previously reported initial results with the HA Hemopatch® in PN. We now report our experiences with Hemopatch® in a la...

journal_title：Advances in therapy

authors： Hupe MC,Büttner M,Tabrizi PF,Merseburger AS,Kuczyk MA,Imkamp F

更新日期：2020-12-04 00:00:00

abstract：INTRODUCTION:To determine patient and rheumatologist preferences for rheumatoid arthritis (RA) treatment attributes in Spain and to evaluate their attitude towards shared decision-making (SDM). METHODS:Observational, descriptive, exploratory and cross-sectional study based on a discrete choice experiment (DCE). To ide...

journal_title：Advances in therapy

authors： Díaz-Torné C,Urruticoechea-Arana A,Ivorra-Cortés J,Díaz S,Dilla T,Sacristán JA,Inciarte-Mundo J,Comellas M,Prades M,Lizán L

更新日期：2020-04-01 00:00:00

abstract：INTRODUCTION:Infantile hemangiomas (IH) are the most common benign vascular tumors of childhood, with an incidence of 5-10% during the first year of age. Propranolol is considered the first-line treatment for this condition. Potentially there is a high probability of negative results to therapy, because in many countri...

journal_title：Advances in therapy

authors： Castaneda S,Melendez-Lopez S,Garcia E,De la Cruz H,Sanchez-Palacio J

更新日期：2016-10-01 00:00:00

abstract：INTRODUCTION:This retrospective study evaluates the efficacy of palliative chemotherapy with a modified docetaxel, cisplatin, 5-fluorouracil (5-FU; "TPF" regimen) regimen (mTPF; reduced doses of docetaxel, cisplatin, and 5-FU with reduction of intravenous 5-FU from 4 days to 2 days) in Asian patients with recurrent and...

journal_title：Advances in therapy

authors： Lin JT,Lai GM,Chang TH,Liu MT,Bi CP,Wang JW,Chen MK

更新日期：2012-01-01 00:00:00

abstract：BACKGROUND:Adherence to disease-modifying therapies (DMTs) is essential for the reduction of multiple sclerosis (MS) progression and relapse. However, only limited data currently exist on the impact of treatment adherence on MS-related clinical and economic outcomes in the real world setting. OBJECTIVE:To assess the i...

journal_title：Advances in therapy

authors： Tan H,Cai Q,Agarwal S,Stephenson JJ,Kamat S

更新日期：2011-01-01 00:00:00

abstract：:Unfortunately, the fourteenth author's name was incorrectly published in the Original Article. The correct author name is Cen Hong. ...

journal_title：Advances in therapy

authors： Qi X,Li Y,Wang R,Lin L,Li J,Wang L,Zheng S,Sun Y,Zhao L,Fu X,Wang M,Qiu X,Deng H,Hong C,Li Q,Li H,Guo X

更新日期：2019-08-01 00:00:00

abstract：INTRODUCTION:This study aimed to demonstrate the clinical utility of non-invasive multigene Cxbladder urine tests in reducing the overall number of diagnostic tests and invasive procedures used in the clinical evaluation of patients presenting with microhematuria, a key symptom of urothelial carcinoma (UC). There is a ...

journal_title：Advances in therapy

authors： Darling D,Luxmanan C,O'Sullivan P,Lough T,Suttie J

更新日期：2017-05-01 00:00:00

abstract：:Atrial fibrillation (AF) and venous thromboembolism (VTE) are highly prevalent and relevant healthcare issues. Direct oral anticoagulants (DOACs) are now the first-choice for anticoagulant treatment of these conditions displaying a better efficacy/safety profile than vitamin-K antagonists, mainly due to significantly ...

journal_title：Advances in therapy

authors： Ballestri S,Capitelli M,Fontana MC,Arioli D,Romagnoli E,Graziosi C,Lonardo A,Marietta M,Dentali F,Cioni G

更新日期：2020-05-01 00:00:00

abstract：INTRODUCTION:Ample evidence suggested a role of sigma-1 receptor in affective disorders since the interaction of numerous antidepressants with sigma receptors was discovered. A recent study on Japanese subjects found a genetic variant within the encoding gene SIGMAR1 (rs1800866A>C) associated with major depressive diso...

journal_title：Advances in therapy

authors： Mandelli L,Wang SM,Han C,Lee SJ,Patkar AA,Masand PS,Pae CU,Serretti A

更新日期：2017-03-01 00:00:00

abstract：:The present study, which was designed as a prospective, double-masked, randomized, controlled, single-site study, was conducted to compare the effects of 3 approved ophthalmic nonsteroidal anti-inflammatory drugs-nepafenac ophthalmic suspension 0.1% (Nevanac; Alcon Laboratories, Inc., Fort Worth, Tex), ketorolac trome...

journal_title：Advances in therapy

authors： Durrie DS,Kennard MG,Boghossian AJ

更新日期：2007-11-01 00:00:00

abstract：INTRODUCTION:Pulmonary arterial hypertension (PAH) is associated with poor prognosis despite significant recent advances in its treatment. An intravenous formulation of epoprostenol sodium containing glycine and mannitol (epoprostenol GM; GlaxoSmithKline, London, UK) is widely used to treat PAH. A new formulation of ep...

journal_title：Advances in therapy

authors： Tamura Y,Ono T,Fukuda K,Satoh T,Sasayama S

更新日期：2013-05-01 00:00:00

abstract：INTRODUCTION:This analysis of pooled data from four randomized, controlled-dose adjustment, phase 3 studies (three 15-week, double-blind, placebo- and active-controlled studies and a 1-year, open-label, active-controlled safety study) in patients with chronic osteoarthritis hip or knee pain or low back pain evaluated t...

journal_title：Advances in therapy

authors： Etropolski M,Kuperwasser B,Flügel M,Häufel T,Lange B,Rauschkolb C,Laschewski F

更新日期：2014-06-01 00:00:00

abstract：:As head and neck squamous cell carcinoma (HNSCC) patients with distant metastases (DM) were generally treated only palliatively, the value of screening for DM was usually limited to attempts to avoid extensive locoregional treatment when DM were present pretreatment. Recently, the concept of treating oligometastases, ...

journal_title：Advances in therapy

authors： de Bree R,Senft A,Coca-Pelaz A,Kowalski L,Lopez F,Mendenhall W,Quer M,Rinaldo A,Shaha AR,Strojan P,Takes RP,Silver CE,Leemans CR,Ferlito A

更新日期：2018-02-01 00:00:00

abstract：:Designed to provide information about patients with schizophrenia who switch from depot neuroleptics to the oral, atypical antipsychotic risperidone, this multicenter observational study enrolled patients who wished to stop the depot, had an unsatisfactory response, or experienced unacceptable side effects. Individual...

journal_title：Advances in therapy

authors： Desai NM,Huq Z,Martin SD,McDonald G

更新日期：1999-03-01 00:00:00

abstract：INTRODUCTION:Liraglutide has been widely used in the treatment of type 2 diabetes mellitus (T2DM), however, the results of a number of randomized placebo-controlled trials on the effects of liraglutide for the treatment of T2DM have varied. The purpose of this study was to assess the effects of liraglutide versus place...

journal_title：Advances in therapy

authors： Du Q,Wang YJ,Yang S,Zhao YY,Han P

更新日期：2014-11-01 00:00:00

abstract：:Knee osteoarthritis (KOA) is the most common musculoskeletal disorder, especially in middle up to old age. KOA also results in many complications like changes in gait. Nowadays, changes in lifestyle and the reduced physical activity make people more vulnerable to KOA. Therefore, considering the increasing prevalence o...

journal_title：Advances in therapy

authors： Ganjeh S,Rezaeian ZS,Mostamand J

更新日期：2020-08-01 00:00:00

abstract：INTRODUCTION:nab-Paclitaxel plus gemcitabine (nab-P + G) and FOLFIRINOX (FFX) are among the most common first-line (1L) therapies for metastatic adenocarcinoma of the pancreas (MPAC), but real-world data on their comparative effectiveness are limited. METHODS:This retrospective cohort study compared the efficacy and s...

journal_title：Advances in therapy

authors： Kim S,Signorovitch JE,Yang H,Patterson-Lomba O,Xiang CQ,Ung B,Parisi M,Marshall JL

更新日期：2018-10-01 00:00:00

abstract：INTRODUCTION:This study of UK patients examines clinical, health-related quality of life (HRQOL) and economic outcomes associated with iron chelation therapy (ICT). Desferrioxamine (DFO) (Desferal; Novartis, Switzerland) and Deferiprone (Ferriprox; Apotex, Canada) are ICTs used to treat iron overload. DFO requires 8-to...

journal_title：Advances in therapy

authors： Payne KA,Rofail D,Baladi JF,Viala M,Abetz L,Desrosiers MP,Lordan N,Ishak K,Proskorovsky I

更新日期：2008-08-01 00:00:00

abstract：:The origin of chronic periodontal disease is strongly related to the nature and physiology of the subgingival bacterial biofilm, of which Porphyromonas gingivalis is a main protagonist. This study was conducted in vitro, to test the susceptibility of the W83 strain of P gingivalis to several oral antiseptics, bearing ...

journal_title：Advances in therapy

authors： Bercy P,Lasserre J

更新日期：2007-11-01 00:00:00

abstract：INTRODUCTION:Phase IV post-marketing surveillance studies are needed to evaluate the real-world safety and effectiveness of drug products. This study aimed to evaluate the safety and effectiveness of biosimilar etanercept (Altebrel, AryoGen Co., Iran) in patients with rheumatoid arthritis (RA), ankylosing spondylitis (...

journal_title：Advances in therapy

authors： Gharibdoost F,Salari AH,Salesi M,Ebrahimi Chaharom F,Mottaghi P,Hosseini M,Sahebari M,Nazarinia M,Mirfeizi Z,Shakibi M,Moussavi H,Karimifar M,Mowla K,Karimzadeh H,Anjidani N,Jamshidi A

更新日期：2021-01-11 00:00:00

abstract：INTRODUCTION:Increasing dialysate magnesium (D-Mg2+) appears to be an intriguing strategy to obtain cardiovascular benefits in subjects with end-stage kidney disease (ESKD) on hemodialysis. To date, however, hemodialysis guidelines do not suggest to increase D-Mg2+ routinely set at 0.50 mmol/L. METHODS:A randomized 4-...

journal_title：Advances in therapy

authors： Del Giorno R,Lavorato Hadjeres S,Stefanelli K,Allegra G,Zapparoli C,Predrag L,Berwert L,Gabutti L

更新日期：2020-12-01 00:00:00

abstract：:Low- and middle-income countries (LMICs) are challenged with a disproportionately high burden of noncommunicable diseases (NCDs) and limited healthcare resources at their disposal to tackle the NCD epidemic. Understanding the patient journey for NCDs from the patients' perspective can help healthcare systems in these ...

journal_title：Advances in therapy

authors： Devi R,Kanitkar K,Narendhar R,Sehmi K,Subramaniam K

更新日期：2020-12-01 00:00:00

abstract：INTRODUCTION:The aim of this study was to investigate whether the efficacy of liraglutide observed in randomized controlled trials translates into therapeutic benefits in the French population during routine clinical practice. METHODS:This observational, prospective, multicenter study included 3152 adults with type 2 ...

journal_title：Advances in therapy

authors： Gautier JF,Martinez L,Penfornis A,Eschwège E,Charpentier G,Huret B,Madani S,Gourdy P

更新日期：2015-09-01 00:00:00

abstract：INTRODUCTION:Rivastigmine is a cholinesterase inhibitor, approved for the treatment of mild-to-moderate dementia of Alzheimer's type. This study assessed the short- and long-term effectiveness and safety of rivastigmine in patients with mild-to-moderate Alzheimer's disease (AD) in a real-world clinical setting in Taiwa...

journal_title：Advances in therapy

authors： Chang CC,Peng GS,Lai TJ,Li CH,Liu CK

更新日期：2019-06-01 00:00:00

abstract：INTRODUCTION:Pigmented villonodular synovitis (PVNS), also known as giant-cell tumour of the tendon sheath (GCTT), is a rare, benign proliferative tumour affecting the inner lining of synovial joints and tendon sheets. Information on treatment needs of PVNS patients to inform drug development is currently scarce. We co...

journal_title：Advances in therapy

authors： Cook NS,Landskroner K,Shah B,Walda S,Weiss O,Pallapotu V

更新日期：2020-06-01 00:00:00